Therapeutic Immunomodulation of Tumor-Lymphatic Crosstalk via Intratumoral Immunotherapy
Open Access
- 31 October 2024
- journal article
- review article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (12) , 5929-5943
Abstract
Intra- and peritumoral lymphatics and tumor-draining lymph nodes play major roles in mediating the adaptive immune response to cancer immunotherapy. Despite this, current paradigms of clinical cancer management seldom seek to therapeutically modulate tumor-lymphatic immune crosstalk. This review explores recent developments that set the stage for how this regulatory axis can be therapeutically manipulated, with a particular emphasis on tumor-localized immunomodulation. Building on this idea, the nature of tumor-lymphatic immune crosstalk and relevant immunotherapeutic targets and pathways are reviewed, with a focus on their translational potential. Engineered drug delivery systems that enhance intratumoral immunotherapy by improving drug delivery to both the tumor and lymph nodes are also highlighted.Keywords
Funding Information
- National Institutes of Health (R01CA207619, R01CA247484, R01HL173943, T32GM008433)
This publication has 141 references indexed in Scilit:
- Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph NodesJAMA Oncology, 2023
- Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced MelanomaJAMA Oncology, 2023
- In Situ Tumor Vaccine for Lymph Nodes Delivery and Cancer Therapy Based on Small Size NanoadjuvantSmall, 2023
- First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignanciesInternational Journal of Cancer, 2019
- Nanoparticle‐Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral ResponsesAdvanced Materials, 2018
- Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II studyCancer Immunology, Immunotherapy, 2015
- A novel RNA‐based adjuvant combines strong immunostimulatory capacities with a favorable safety profileInternational Journal of Cancer, 2014
- Lymphoscintigraphy2014
- Intratumoral interleukin-2/agonist CD40 antibody drives CD4+-independent resolution of treated-tumors and CD4+-dependent systemic and memory responsesCancer Immunology, Immunotherapy, 2011
- High response rate after intratumoral treatment with interleukin‐2Cancer, 2010